title: Severe adalimumab-induced thrombocytopenia in a patient with Crohn's disease.
abstract: Crohn's disease is a chronic transmural inflammatory disorder characterized by inflammation of the intestine. Anti-TNF-α drugs are used for induction and maintenance of remission in patients with this condition. Thrombocytopenia is an uncommon side effect of treatment with anti-TNF-α drugs. We report the case of a 71-year-old woman diagnosed with Crohn's disease who developed severe adalimumab-induced thrombocytopenia and who did not respond to standard therapy for thrombocytopenia.
authors.affiliation: Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa, Spain. mjcasanova.g@gmail.com
authors.forename: M J
authors.initials: MJ
authors.lastname: Casanova
authors.forename: M
authors.initials: M
authors.lastname: Chaparro
authors.forename: S
authors.initials: S
authors.lastname: Martínez
authors.forename: I
authors.initials: I
authors.lastname: Vicuña
authors.forename: J P
authors.initials: JP
authors.lastname: Gisbert
mesh_terms: D000068879:Adalimumab; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D006801:Humans; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000628:therapy
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab